Physician profile
Karen Smith
NPI 1033112164
$1,351.59
in general payments reported to CMS, 2019-2025
27 companies · $167 in 2025
The $167 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $93.91 · 2021: $308 · 2022: $220 · 2023: $291 · 2024: $162 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $618.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $269.50 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $136.09 | 2019-2025 | |
| Exact Sciences Corporation | $104.35 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $101.83 | 2019-2024 | Arexvy, Shingrix, Bexsero |
| Abbott Laboratories | $101.70 | 2021-2023 | Coroflow |
| Lilly USA, LLC | $94.29 | 2020-2024 | Mounjaro, Zepbound |
| Corcept Therapeutics | $66.57 | 2023-2025 | Korlym |
| Scilex Pharmaceuticals INC. | $62.97 | 2019-2023 | Ztlido |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.35 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $44.00 | 2019-2024 | Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $40.10 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $27.50 | 2020-2022 | |
| Indivior INC. | $24.13 | 2023 | Sublocade |
| Amgen INC. | $23.86 | 2020-2021 | |
| Inspire Medical Systems, INC. | $22.62 | 2023 | Inspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $21.70 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.85 | 2023 | Nuedexta |
| Axsome Therapeutics, INC. | $18.75 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $18.67 | 2023 | Delstrigo, Dificid, Pifeltro |
| Kaleo, INC. | $16.21 | 2019 | |
| Daiichi Sankyo INC. | $14.82 | 2019 | |
| Organon LLC | $14.25 | 2022 | |
| Shield Therapeutics INC | $13.65 | 2023 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $13.53 | 2024 | |
| Biodelivery Sciences International, INC. | $13.32 | 2020 | |
| Abbvie INC. | $13.14 | 2020 | |
| Phathom Pharmaceuticals, INC. | $6.84 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.